AnaptysBio, Inc. (ANAB)
56.28
-1.01
(-1.76%)
USD |
NASDAQ |
Aug 28, 16:00
56.18
-0.10
(-0.17%)
After-Hours: 20:00
AnaptysBio Total Assets (Quarterly) : 329.68M for March 31, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 329.68M |
| December 31, 2025 | 364.40M |
| September 30, 2025 | 353.10M |
| June 30, 2025 | 335.25M |
| March 31, 2025 | 422.05M |
| December 31, 2024 | 483.83M |
| September 30, 2024 | 493.42M |
| June 30, 2024 | 427.38M |
| March 31, 2024 | 405.84M |
| December 31, 2023 | 452.39M |
| September 30, 2023 | 487.33M |
| June 30, 2023 | 517.10M |
| March 31, 2023 | 551.79M |
| December 31, 2022 | 610.38M |
| September 30, 2022 | 618.50M |
| June 30, 2022 | 603.85M |
| March 31, 2022 | 625.17M |
| December 31, 2021 | 643.07M |
| September 30, 2021 | 424.34M |
| June 30, 2021 | 426.57M |
| March 31, 2021 | 396.42M |
| December 31, 2020 | 416.55M |
| September 30, 2020 | 384.75M |
| Date | Value |
|---|---|
| June 30, 2020 | 401.75M |
| March 31, 2020 | 424.23M |
| December 31, 2019 | 435.20M |
| September 30, 2019 | 451.50M |
| June 30, 2019 | 480.15M |
| March 31, 2019 | 494.23M |
| December 31, 2018 | 509.00M |
| September 30, 2018 | 523.12M |
| June 30, 2018 | 306.02M |
| March 31, 2018 | 314.84M |
| December 31, 2017 | 329.36M |
| September 30, 2017 | 121.94M |
| June 30, 2017 | 130.41M |
| March 31, 2017 | 131.11M |
| December 31, 2016 | 62.18M |
| September 30, 2016 | 55.84M |
| June 30, 2016 | 58.50M |
| March 31, 2016 | 54.72M |
| December 31, 2015 | 56.28M |
| September 30, 2015 | 60.88M |
| June 30, 2015 | 22.29M |
| March 31, 2015 | 22.80M |
| December 31, 2014 | 25.06M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| 4D Molecular Therapeutics, Inc. | 492.62M |
| Design Therapeutics, Inc. | 215.13M |
| Inhibrx Biosciences, Inc. | 154.22M |
| Agenus, Inc. | 172.69M |
| Amgen, Inc. | 95.64B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 316.94M |
| Shareholders Equity (Quarterly) | 12.75M |
| Debt to Equity Ratio | 21.76 |
| Current Ratio | 7.580 |
| Net Debt Paydown Yield | 1.72% |